Vanguard Group’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$23.2M Buy
2,229,539
+82,480
+4% +$828K ﹤0.01% 2548
2025
Q3
$19.3M Sell
2,147,059
-131,406
-6% -$1.15M ﹤0.01% 2645
2025
Q2
$29.6M Sell
2,278,465
-113,587
-5% -$1.71M ﹤0.01% 2371
2025
Q1
$60.4M Buy
2,392,052
+8,504
+0.4% +$253K ﹤0.01% 2015
2024
Q4
$81.9M Buy
2,383,548
+96,464
+4% +$4.35M ﹤0.01% 1948
2024
Q3
$113M Buy
2,287,084
+279,146
+14% +$14.3M ﹤0.01% 1820
2024
Q2
$121M Buy
2,007,938
+483,428
+32% +$27.6M ﹤0.01% 1748
2024
Q1
$78.6M Buy
1,524,510
+40,500
+3% +$1.99M ﹤0.01% 1978
2023
Q4
$59.8M Buy
1,484,010
+50,057
+3% +$1.47M ﹤0.01% 2112
2023
Q3
$40M Buy
1,433,953
+255,150
+22% +$7.61M ﹤0.01% 2236
2023
Q2
$33.9M Buy
1,178,803
+159,310
+16% +$3.54M ﹤0.01% 2361
2023
Q1
$17M Buy
1,019,493
+223,228
+28% +$3.15M ﹤0.01% 2662
2022
Q4
$10.1M Sell
796,265
-6,484
-0.8% -$78.9K ﹤0.01% 2943
2022
Q3
$9.63M Buy
802,749
+130,694
+19% +$1.79M ﹤0.01% 2968
2022
Q2
$9.46M Buy
672,055
+33,242
+5% +$438K ﹤0.01% 3018
2022
Q1
$7.91M Buy
638,813
+301,055
+89% +$3.61M ﹤0.01% 3277
2021
Q4
$3.8M Sell
337,758
-69,795
-17% -$839K ﹤0.01% 3765
2021
Q3
$5.16M Buy
+407,553
New +$5.61M ﹤0.01% 3637

Other funds holding RXST

Vanguard Group's RXST Position: Q4 2025 in Review

Vanguard Group increased its RxSight (RXST) stake by 3.8% in Q4 2025, buying an estimated $828K and bringing the position to 2,229,539 shares worth $23.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2548.

Vanguard Group first reported a position in RXST in Q3 2021 and has held it in 18 quarters since. The position peaked at $121M in Q2 2024. 163 funds tracked by Wall St. Rank hold RXST as of Q4 2025.

  • Vanguard Group held 2,229,539 shares of RxSight worth $23.2M as of Q4 2025.
  • Vanguard Group bought 82,480 RxSight shares in Q4 2025, an estimated $828K.
  • RxSight made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2548 holding.
  • Vanguard Group first reported a position in RxSight in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's RxSight position peaked at $121M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held RxSight as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.